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 ABSTRACT 
BACKGROUND 
Catheter-based renal denervation (RDN) is a potential modality in the treat-
ment of patients with resistant hypertension (RH). The biological effects of 
RDN are not fully comprehended and studies examining its impact on blood 
pressure (BP) and other cardiovascular surrogate markers have generated 
conflicting results.  
AIMS 
Study I aimed to assess coronary flow reserve (CFR) in patients with RH. 
Study II was performed in order to estimate the effect of RDN on CFR. In 
Study III, we examined the safety and efficacy of RDN in a real-world set-
ting. Study IV aimed to estimate the impact of RDN on muscle sympathetic 
nerve activity (MSNA). 
METHODS 
We assessed CFR in 25 patients with RH and matched controls with con-
trolled hypertension in Study I. In Study II, we used the same modality in 26 
patients with RH, before and six months after RDN. In Study III, we used 
data from the Swedish Registry for Renal Denervation. In Study IV, we as-
sessed MSNA at rest and during mental stress in patients with RH before 
and six months after intervention.  
RESULTS 
RH was associated with impaired CFR as compared to patients with con-
trolled hypertension (I). Despite a significant reduction in BP, we did not 
detect any significant changes in CFR six months after RDN (II). Registry 
analysis showed significant reduction in office and ambulatory blood pres-
sure six months after RDN. The procedure proved feasible and was associat-
ed with a low complication rate (III). No significant changes in MSNA at 
rest and mental stress were noted at six-month follow-up (IV).  
CONCLUSIONS 
RH is associated with an impairment of the coronary microcirculation, 
which may contribute to the increased risk of cardiovascular events in this 
patient group. RDN did not change the course of CFR, despite a significant 
reduction in BP. Registry data suggest a sustained reduction in both office 
and ambulatory BP. MSNA was unchanged at follow-up, which raises ques-
tions about the biological effects of RDN and its impact on the autonomous 
nervous system.  
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SAMMANFATTNING PÅ SVENSKA 
Bakgrund och syfte 
Kateterbaserad renal denervering (RDN) är en metod i behandlingen av pati-
enter med resistent hypertoni (RH). De biologiska effekterna är inte helt 
kartlagda och studier avseende blodtryck har visat motstridande resultat. 
Avhandlingsarbetet syftar till att belysa effekten på utvalda kardiovaskulära 
surrogatmarkörer och närmare kartlägga mekanismen bakom RDN. 
Metoder 
Delarbete I beskriver hjärtats koronarflödesreserv (CFR) i patienter med RH 
i jämförelse med kontrollerad hypertoni. I delarbete II bestämdes CFR i pa-
tienter med RH före och sex månader efter RDN. Delarbete III är en nation-
ell registerstudie där vi analyserade data från Svenska Registret för Renal 
Denervering avseende säkerhet och blodtryckseffekt. I delarbete IV använ-
des mikroneurografi för att mäta muskelsympatisk nervaktivitet (MSNA) i 
patienter med RH. MSNA utfördes i vila och vid mental stress, före och sex 
månader efter RDN.  
Resultat 
RH var associerat med lägre CFR jämfört med patienter med kontrollerad 
hypertoni (I). RDN medförde en minskning av blodtryck men hade ingen 
signifikant effekt på CFR vid sex-månaders-uppföljning (II). Registerana-
lysen visade en ihållande minskning av både office- och 24-
timmarsblodtryck. Ingreppet förefaller säkert och är associerat med ett lågt 
antal komplikationer (III). MSNA i vila och vid mental stress var oförändrat 
sex månader efter RDN (IV). 
Slutsatser 
RH är associerat med en nedsatt kardiell mikrocirkulation vilket kan bidra 
till patientgruppens höga risk för kardiovaskulära händelser (I). RDN med-
förde ingen effekt på CFR trots en kliniskt betydande blodtryckssänkning 
(II). Den första svenska registeranalysen visar en ihållande och potentiellt 
betydelsefull blodtrycksminskning efter RDN (III). MSNA förblev oföränd-
rat efter RDN, både i vila och vid mental stress-provokation. Resultaten 
stödjer därmed inte den rådande hypotesen om verkningsmekanismen 
bakom RDN (IV). 
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INTRODUCTION 
1.1 Arterial hypertension 
 
Arterial hypertension is the leading risk factor for cardiovascular disease. It ac-
counts for nearly 10 million deaths annually and as prevalence continues to in-
crease, hypertension represents one of the major public health issues world-wide 
(1).  
 
1.2 Resistant hypertension 
 
Resistant hypertension (RH) is commonly defined as uncontrolled office blood 
pressure (BP) (>140/90 mmHg), despite treatment with three antihypertensive 
agents including one diuretic (2). Alternative definitions include patients with 
controlled BP while being treated with at least four antihypertensive drugs (3). 
 
Prevalence 
 
The prevalence of drug-resistant hypertension ranges from 9-15 % of all patients 
with hypertension, depending on the population and applied definition of RH (4-
7). 
 
Etiology 
 
The term RH implies resistance to pharmacological treatment in the absence of 
secondary causes. These secondary causes include primary hyperaldosteronism, 
renal artery stenosis, phaechromocytoma, thyroid disease, Cushing´s syndrome, 
intracranial tumours and coarctation of the aorta, and these are to be excluded 
during clinical work-up (8). 
 
RH can be real or merely apparent (9). Apparent forms, also labelled pseudo-
resistance, may be caused by (i) poor medical adherence, (ii) white-coat hyper-
tension, (iii) incorrect BP measurement technique, and (iv) substandard antihy-
pertensive pharmacological treatment. 
 
True resistant hypertension (TRH), i.e. RH after exclusion of pseudo-resistance 
and potential secondary causes, is commonly of multifactorial origin. As in es-
sential hypertension, not one primary cause is found in the majority of patients. 
However, previous studies have identified age, obesity, chronic kidney disease,  
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diabetes and socioeconomic status as predictors for lack of BP-control and repre-
sent common patient features in RH (7, 10-12). 
 
Prognosis 
 
RH is associated with a high prevalence of left ventricular hypertrophy, chronic 
kidney failure (13) and an increased risk of cardiovascular morbidity and mortal-
ity when compared with controlled hypertensives (6, 14).  
 
However, most of the above data are either observational or represent sub-group 
analyses of trials which were not specifically designed for RH. In order to con-
tribute to a more profound understanding of the characteristics of RH, we per-
formed Study I. 
 
Conventional treatment 
 
As RH is commonly multifactorial in origin, treatment modalities aim to cover a 
range of treatment aspects. In line with the recommendations for essential hyper-
tension, lifestyle-changes including a low-salt diet, weight loss, moderated alco-
hol-intake and regular physical exercise are advocated. Concurrent medication 
that interferes with BP control and its physiological determinants, should be 
withdrawn (3).  
 
The effect of pharmacological treatment in patients with RH has not been evalu-
ated specifically in any outcome-study. However, pharmacological treatment 
effects are assumed to be substantial and in line with the previously published 
landmark trials in hypertension (15, 16).  
 
As to the choice of drug combination, guidelines advocate a combination of 
drugs with complementary mechanisms of action, namely ACE-inhibitors plus 
calcium channel blockers and a thiazide diuretic (”A+C+D”) (17). The recently 
published PATHWAY-2 trial, dedicated to the comparison of additive drug 
treatment in diagnosed RH, has demonstrated superior complementary BP-
effects of spironolactone as compared with alpha- and beta-blockers, thus sup-
porting its use as the additional drug of choice in treatment of RH (18). 
 
 
1.3 Sympathetic nerve activity and hypertension 
 
Patients with RH are commonly characterised by a significant number of comor-
bidities. Associated diseases include diabetes mellitus, heart failure and chronic 
renal failure (7). These comorbidities are independently associated with varying 
degrees of sympathoexcitation (19, 20), which contributes to the chronic adren-
ergic burden that is considered a common trait in patients with RH (21). 
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Sympathetic nervous activity is integrated within the nucleus tractus solitarius, 
located in the brain-stem, which is cross-linked in a tight network of efferent and 
afferent nerve fibers leading to and from peripheral organs such as the heart, 
liver, blood vessels and kidneys (Fig. 1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 Interplay of key-organs contributing to blood pressure regulation by means of the au-
tonomous nervous system. From (22) with permission of Elsevier. 
The link between arterial hypertension and autonomous nervous activity has 
been known about since the pre-pharmacological era. In the 1930´s and 1940´s, 
surgical sympathectomy by means of surgical thoracolumbar splanchnicectomy 
constituted one of few available treatment modalities in patients with hyperten-
sion. Marked effects on BP were noted, however the invasive and non-selective 
nature of the method implied a significant periprocedural risk, as well as consid-
erable side-effects (23).  
In the modern era, Esler et al. were able to consolidate earlier findings and estab-
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lish an important pathophysiological link between hypertension and sympathetic 
nerve activity by showing increased sympathoexciation in individuals with hy-
pertension as compared to the normotensive controls (24) (Fig. 2).  
 
 
 
 
Figure 2 Renal sympathetic activity assessed by renal norepinephrine spillover measurement in 
patients with hypertension and normotensive controls. From (25) with permission of the Ameri-
can Society of Physiology. 
 
Sympathetic nerve activity and cardiovascular reactivity 
 
Mental stress induces transient changes in heart rate (HR) and BP, termed cardi-
ovascular reactivity. Abnormal cardiovascular reactivity is associated with an 
increased risk of the development of hypertension in normotensives (26, 27) and 
borderline hypertensives (28, 29).  Furthermore, it is considered an important 
aspect of essential hypertension (30) and implies an increased risk of cardiovas-
cular events (31). 
 
The importance of mental stress reaction in patients with advanced stages of 
hypertension is unclear, and this fact constituted the rationale for Study IV. 
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1.4 Renal sympathetic nerve activity  
 
Renal sympathetic nerve activity is an important contributor to the development 
and maintenance of arterial hypertension and has been the subject of medical 
research since the beginnings of modern experimental physiology in the 19th 
century (32). 
 
Efferent renal sympathetic nerve activity 
 
Efferent renal sympathetic nerve fibres originate from the brain stem and travel 
via sympathetic ganglia along the adventitia of the renal artery to the kidney, 
innervating vasculature, renal tubules and the renin-containing juxtaglomerular 
cells (33).   
 
Claude Bernard was the first, in 1859, to discover that cutting the greater 
splanchnic nerve (i.e. renal sympathetic denervation) produced ipsilateral diure-
sis whereas electrical stimulation of its peripheral cut end led to a marked ipsi-
lateral antidiuresis (34). More than a century later, these findings were confirmed 
and further specified by DiBona et al., who demonstrated the relationship be-
tween selective renal nerve stimulation and renal blood flow, renin- and sodium-
secretion- factors deemed vital for the regulation of systemic blood pressure (33) 
(Fig. 3). 
 
 
 
	
 
Figure 3 Relationship between renal nerve stimulation and renin secretion, sodium retention 
and renal blood flow. From (33) with permission of the American Physiological Society. 
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Afferent renal sympathetic nerve activity 
Afferent sensory fibers originate from the renal pelvis and interstitium, collect-
ing stimuli from renal mechano- and chemoreceptors. An increase in afferent 
renal sympathetic nerve activity is triggered by renal injury such as inflamma-
tion, ischemia, oxidative stress and acidosis (25), leading to an increase in cen-
tral sympathetic nerve activity within the mechanics of a centro-renal feed-back-
loop. Subsequent vasoconstriction and an increase in sodium retention then bring 
about an increase in arterial blood pressure. Converse et al. confirmed this con-
cept, showing marked reductions in central sympathetic nerve activity and BP in 
patients after renal transplantation, including bilateral nephrectomy (i.e. renal 
sympathetic denervation) as compared to those after renal transplantation only 
(19) (Fig. 4). 
 
 
 

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Consecutive studies, performed in various animal-models of hypertension, have 
confirmed and extended existing evidence on surgical and chemical renal sym-
pathetic denervation and their BP-lowering properties (25) (Table 1).
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Models of experimental hypertension in which renal denervation 
prevents or delays the development of hypertension 
 
Spontaneously hypertensive rat  
Borderline hypertensive rat 
New Zealand SHR 
Goldblatt 2K, 1C (rat) 
Aortic coarctation (dog) 
Aortic nerve transection (rat) 
DOCA-NaCl (rat) 
DOCA (pig) 
Grollman renal wrap (rat) 
Low sodium, 1K hypertension (rat) 
Angiotensin II hypertension (rat) 
Obesity hypertension (dog) 
NaCl (baroreflex-impaired rabbit) 
 
Table 1 Overview of models of experimental hypertension in the context of RDN. Modified from 
(25) with permission of the American Physiological Society. 
 
1.5 Renal sympathetic denervation 
 
Based on the above findings, a catheter-based, endovascular method has been 
developed to selectively decrease renal sympathetic nerve activity (5). Both af-
ferent and efferent sympathetic nerves travel within the renal artery adventitia, 
surrounding the vessel’s circumference in a net-like fashion (Fig. 5). The selec-
tive disruption of nerve fibre traffic and consecutive inhibition of renal sympa-
thetic nerve activity constitutes the rationale behind renal denervation (RDN).   
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Renal denervation: Treatment modalities 
The majority of available scientific data is based on the first generation Sym-
plicity-Flex device (Medtronic, Mountain View, CA, USA) (Fig. 6) (35). As 
with most of the seven available denervation techniques, the Flex-catheter ap-
plies radiofrequency energy to directly heat contacted tissue areas, as well as 
induce a passive, subacute thermal conduction into deeper layers of the vessel 
wall (36). Other devices, using RF-energy in a modified catheter-setup, include 
the second generation Symplicity-Spyral (Medtronic, Mountain View, CA, 
USA) (37), the EnligHTN- (St. Jude Medical, St. Paul, MI, USA) (38) the One-
Shot- (Covidien, Dublin, Ireland) (39), and the Vessix-system (Boston Scien-
tific, Marlborough, MA, USA) (40). The remaining devices are based on focused 
high-frequency ultrasound as the energy source and include the Paradise catheter 
(ReCor Medical, Palo Alto, CA, USA) and the Kona Medical Surround Sound 
System (Kona Medical, Bellevue, Washington, USA) (41). 
 
Head-to-head comparisons between different catheter devices regarding safety, 
efficacy and feasibility are not available, which is one of the reasons for the ini-
tiation of Study III. 
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Renal denervation: Effects on the sympathetic nervous sys-
tem 
There are different modalities to assess human sympathetic nerve activity. Assess-
ment of organ-specific, renal norepinephrine spillover is a technically challenging, 
invasive method, which aims primarily to evaluate kidney-specific efferent sympa-
thetic nerve activity (42). In the context of renal denervation, reductions in renal 
norepinephrine spillover post-intervention have been reported, but are restricted to 
case-based publications (35, 43). 
 
The disruption of afferent renal nerve traffic and the consecutive resetting of central 
sympathetic nerve activity, constitute the major rationale for the potential BP-
reducing properties of renal denervation (44). These potential changes can be evalu-
ated by microneurographic recordings of muscle sympathetic nerve activity 
""#  VÖLZ
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(MSNA), that provides a direct measurement of efferent sympathetic activity to skin 
and muscle, which is considered the gold standard in the assessment of central sym-
pathetic nerve activity (Figs. 7 and 8). MSNA has previously been investigated by 
several studies, generating conflicting results (45-50). Whether BP changes after 
RDN may be attributed to the inhibition of centrally generated sympathetic nerve 
activity remains a matter of debate and also motivated us to perform Study IV. 


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Renal denervation: Effects on arterial blood pressure 
Randomised controlled trials examining the impact on brachial BP in patients 
with RH have generated conflicting data (35, 51-54). While Dener-HTN showed 
a significant impact of RDN on ambulatory BP in patients with RH after having 
undergone a structured optimisation of antihypertensive drug therapy (51), Sym-
plicity HTN-3, the largest randomised trial in the context of RDN, did not show 
any significant changes post-intervention as compared with sham-control (52). 
However, the results from Symplicty HTN-3 have remained a subject of debate, 
and the study has been criticised for suboptimal procedural precision as well as 
unaccounted medication changes in a significant portion of the study population 
(55). 
 
Registry-based data are a valuable complement to clinical trial data adding in-
formation on the external validity of data acquired in selected trial populations 
(56). In the context of RDN, publications based on observational registry data 
have consistently shown BP reductions in patients with RH up to 12 months af-
ter RDN (57-61).  
 
In order to contribute to these open questions in regard to the BP-lowering abili-
ties of RDN, we established the Swedish Registry for Renal Denervation and 
conducted Study III.  
Renal denervation: Recent developments  
The discrepant BP-effects after RDN have been a matter of discussion, and po-
tential explanatory factors include confounding factors such as lack of technical 
precision, varying degrees of drug adherence, the placebo and Hawthorne-
effects, as well as result-distortion by regression to the mean (62). Furthermore, 
studies have identified certain patient attributes, that may predict response after 
RDN (55, 63).  
 
As a direct result of this debate, the SPYRAL HTN Global Clinical Trial Pro-
gram was designed (37), aiming to address previous trial limitations. In order to 
achieve this goal, the focus was shifted towards less severe forms of hyperten-
sion with less severe comorbidities and less intense comedication.  
 
Data from the first study arm have recently been published and show promising 
results: The randomized, sham-controlled SPYRAL HTN-OFF MED-study 
showed significant BP reductions in patients with hypertension without concom-
itant antihypertensive medication at three-month follow-up (64). These study 
results thereby support the rationale for RDN and its BP-reducing properties. 
However, adequately powered clinical trials in patients with ongoing antihyper-
tensive treatment are still needed to prove the clinical significance of RDN.  
""#  VÖLZ
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Renal denervation: Effects on selected cardiovascular surro-
gate markers 
Studies on the impact of RDN on cardiovascular surrogate markers have shown 
a variety of beneficial effects: RDN is associated with a decrease in left ventricu-
lar mass (LVM) (65, 66), a reduction in aortic pulse-wave velocity (67) and BP 
variability (68, 69) as well as an increase in heart rate-recovery (70). Several of 
these aspects have been observed independently of office BP response, and 
might thus be mediated by a direct modulation of the sympathetic nervous sys-
tem (65, 66).  
1.6 Coronary flow reserve: A cardiovascular surrogate 
marker with prognostic implications 
CFR describes cardiac capacity to adapt to changes in myocardial workload and 
reflects both macro- and microvascular coronary function (Fig. 9). It is consid-
ered a reliable surrogate marker for cardiovascular morbidity and an independent 
predictor for mortality in patients with diabetes (71), coronary artery disease 
(72), and normal and near-normal coronary angiographies (73). CFR is impaired 
in patients in less advanced stages of hypertension (74).   
 
Whether CFR is impaired in patients with RH and whether RDN impacts on this 
prognostically significant surrogate marker constitute the main hypotheses for 
Studies I and II. 
 
 

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AIMS 
Study 1 
To assess CFR in patients with RH. The main study hypothesis was that patients 
with RH would present with an impairment in CFR and that CFR would depend 
on the varying severity of hypertension.  
Study II 
To examine the effects of RDN on CFR in patients with RH and assess whether 
potential changes in CFR are dependent on changes in BP. The study’s main 
hypothesis was that RDN improves CFR at follow-up. 
Study III 
To investigate the safety and efficacy of RDN in a real-world setting. We aimed 
to assess long-term BP changes, long-term safety, potential differences in regard 
to the effect of different ablation systems, and identify predictors for BP re-
sponse after RDN.   
Study IV 
To explore the effect of RDN on MSNA at rest and during mental stress in patients 
with RH. We aimed to test whether (i) RDN decreases MSNA at rest and/or (ii) 
modifies MSNA- and blood pressure-responses to mental stress, and whether the 
inhibition of MSNA during mental stress is a rare response-profile in patients with 
RH (iii). 
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PATIENTS AND METHODS 
All studies were conducted according to the Declaration of Helsinki and ap-
proved by the Regional Research Ethics committee in Gothenburg. All patients 
gave their informed consent to participate. 
Study I 
Twenty-five consecutive patients with RH scheduled for RDN, 25 matched pa-
tients with controlled hypertension and 25 healthy controls underwent CFR as-
sessment by transthoracic Doppler echocardiography at rest and during 
Adenosine infusion. Mean flow velocity was assessed in the left anterior de-
scending artery. Patients with controlled and resistant hypertension were pair-
matched according to age, sex, body-mass-index (BMI), smoking status, diabe-
tes mellitus and ischemic heart disease. Healthy controls were selected with re-
gard to age and sex.  
Study II 
Twenty-six consecutive patients with RH underwent percutaneous renal sympa-
thetic denervation. Assessment of CFR by transthoracic Doppler echocardiog-
raphy was performed in accordance with Study I at baseline and at six-month 
follow-up. 
Study III 
The Swedish Registry for Renal Denervation is an investigator-inititated aca-
demic online database, developed by our group and supported by the Swedish 
authorities. The registry contains 130 variables summarizing baseline patient 
characteristics, procedural details, as well as follow-up data. The database con-
tains patient data from the seven Swedish university hospitals that have per-
formed RDN since 2011 exclusively, thereby providing a nation-wide data set 
with a follow-up of up to five years. 
 
The study population comprised a total of 260 patients, who had undergone 
RDN during the period 2011 - 2015. Two hundred and fifty-seven patients un-
derwent RDN successfully and were included in the data analysis.  
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Study IV 
Fourteen consecutive patients with RH underwent percutaneous renal sympathet-
ic denervation. MSNA, BP and HR at rest and during mental stress were as-
sessed at baseline and six months after RDN. 
Mental stress was induced by a three-minute protocol of forced arithmetics, ini-
tiated verbally by the experimenter and where patients were prompted to respond 
with the right answer in a timely fashion. HR and mean arterial BP were as-
sessed continuously by the volume-clamp method (Finometer ®).  
We acquired a complete data set for eleven patients, who were all included in the 
data analysis. 
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STATISTICS 
Results are expressed as means ± SD if not marked otherwise. Statistical analysis 
was performed with the SPSS Statistics 24.0 (IBM, Armonk, USA) statistical pro-
gram software.  
Study 1 
The Student’s t-test for paired and unpaired comparisons was applied when appro-
priate. A two-sided p-value of < 0.05 was considered statistically significant. Pear-
son’s correlation coefficient was used to assess dependence between quantitative 
variables.  
 
 
Study II 
The sample size was calculated to detect a 10% difference in CFR after intervention 
(α-level p = 0.05, power 80%). The Student’s t-test was applied for paired compari-
sons and a two-sided p-value of < 0.05 was considered as statistically significant. In 
order to test for possible interdependence of categorical variables, Pearson’s chi-
square and Fisher’s exact test were performed. An analysis of dependence between 
quantitative variables was performed by the application of Pearson’s correlation 
coefficient.  
Study III 
Results are presented as mean values ± SD or with 95 % confidence intervals, if not 
otherwise stated. The paired Student’s t-test and repeated measures ANOVA were 
used for comparisons of continuous variables. The Wilcoxon signed-rank test was 
used when normal data distribution could not be assumed. Pearson’s correlation 
coefficient was applied when assessing the dependence between two quantitative 
variables. Multiple linear regression analysis was applied in order to identify predic-
tors of changes in BP. Analysis was performed following a forced entry algorithm 
including age, sex, BMI, estimated glomerular filtration (eGFR; by the MDRD for-
mula), diabetes mellitus, obstructive sleep apnoea, heart failure, isolated systolic 
hypertension (ISH), number of antihypertensive drugs at baseline, treatment with 
mineralo-corticoid-receptor antagonists, baseline pulse pressure, baseline systolic 
office BP, and baseline systolic ABPM, as appropriate. A two-sided p-value of < 
0.05 was considered as significant.  
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Study IV 
The paired and unpaired Student’s t-test and, when appopriate, repeated-measures-
ANOVA were applied for comparisons of continuous variables. A two-sided p-value 
of < 0.05 was considered statistically significant. It was estimated that a total of ten 
patients in a paired analysis would provide a statistical power > 80% to show a clin-
ically relevant reduction of five bursts per minute at follow-up (45).  
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RESULTS 
The main results and conclusions for each study are summarised below. For de-
tails, see the respective manuscript at the end of the thesis.  
Study 1 
CFR was significantly lower in patients with RH when compared with patients 
with controlled hypertension (Fig. 10). Also, systolic office BP was significantly 
higher in patients with RH. No difference was noted in regard to left ventricular 
mass index and baseline mean flow velocity between the two groups with hyper-
tension. 
 
Healthy controls presented with significantly higher CFR, lower baseline mean 
velocity and lower BP when compared to all individuals with hypertension.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10 Distribution of coronary flow reserve in the three study groups. From (75) with per-
mission of Springer-Verlag, Berlin Heidelberg.  
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Study II 
 
Systolic office BP was significantly reduced six months after RDN. No signifi-
cant changes in regard to ambulatory BP were noted at follow-up.  
 
Despite the observed drop in BP, CFR remained unchanged six months after 
RDN. Baseline- and hyperaemic flow velocities did not change significantly at 
follow-up (Fig. 11). No correlation between change in BP and CFR was noted.  
 
 
 
 
 
Figure 11 Individual mean flow velocities at rest and during hyperaemia, at baseline and at fol-
low-up.   
Study III 
 
RDN was associated with sustained office and ambulatory BP reductions 
throughout the study period of 36 months (Fig. 12). Independent of catheter-
type, the procedure was deemed safe and few short-term and no clinically rele-
vant long-term complications were noted. The sole consistent predictor for BP-
response was baseline BP. The use of mineralocorticoid receptor antagonists 
predicted ambulatory BP-response at 12 months.  
 
A high degree of variation in BP change after RDN was observed: In one-third 
of the study population, office BP was reduced by at least 10 mmHg accompa-
nied by ambulatory BP-reductions of at least 5 mmHg. These patients were con-
sidered true responders. Another third of the patients showed a corresponding 
decrease for either office or ambulatory BP, while the remaining third did not 
respond, either in regard to office or ambulatory BP.  
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Figure 12 Systolic office BP 6, 12 and 24 months after renal denervation (* p<0.01). From (76) 
with permission of Wolters Kluwer, Alphen an den Rijn.   
 
Study IV 
 
Significant reductions for office BP six months after RDN were noted.  
 
RDN was not associated with a reduction in resting-MSNA, nor did it change the 
pattern of MSNA during mental stress (Fig. 13). Mental stress induced a signfi-
cant increase in both HR and BP. The extent and pattern of this observed cardio-
vascular reactivity, however, remained unchanged when comparing pre- and 
post-RDN recordings. No correlation between BP response and change in 
MSNA was noted.  
 
MSNA inhibition, i.e. a decrease in MSNA activity during mental stress, was a 
rare phenomenon, occurring in < 20% of all study patients (Fig. 14).  
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Figure 13 Mean arterial BP, HR and MSNA during mental stress before and after renal denerva-
tion.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14:  Mean arterial BP, HR and MSNA during mental stress before and after renal dener-
vation.  
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DISCUSSION 
During this thesis, we have made the attempt to further characterise the group of 
patients with RH (Study I), describe effects of RDN in this particular patient 
group (studies II and III) and finally elucidate its potential mechanisms of action 
(Study IV). 
Coronary flow reserve is impaired in patients with resistant 
hypertension 
 
Study I showed that patients with RH present with impaired CFR, which further 
illustrates and underlines the prognostic implications in this patient group. Inter-
estingly, this difference was noted despite a similar distribution of left ventricu-
lar mass between the two hypertension populations, suggesting cardiac 
microvascular dysfunction as the primary cause of our findings.  
 
The regulation of coronary vessel tone is the result of a multifactorial process, 
promoted by endothelial function (77, 78) and impacted by endothelium-
independent structural changes in the cardiac microvasculature and interstitium 
(79, 80). Furthermore, cardiac afterload and the sympathetic tone (21, 81) are 
contributory elements during cardiac adjustments to changes in myocardial 
workload. Arterial hypertension is linked to changes in both endothelium-
dependent and endothelium independent modes of vasodilation (77-80).  
 
Our study confirms this concept and provides the background for future studies 
dedicated to the significance of the specific aspects of coronary microcirculation 
in patients with resistant hypertension.  
 
 
Coronary flow reserve remains unchanged six months after 
renal denervation 
 
The regulation of CFR is a multifactorial process. Factors, that predict the capac-
ity to adapt myocardial perfusion to an increase in work-load include age, sex, 
smoking status, BMI (82) and comorbidities such as diabetes mellitus (71), cor-
onary artery disease (72), left ventricular hypertrophy and the presence of arteri-
al hypertension (74, 83).  
 
 
	SEBASTIAN  VÖLZ	
34 
While we aimed to assess the particular role of RH in the context of Study I, 
Study II was performed to measure renal denervation’s impact on CFR and as-
sess whether these potential changes correlate with changes in BP. 
 
Despite a signficant reduction in office BP, CFR remained unchanged at follow-
up. Potential explanations for this finding include: (i) Our patient population 
presented with a high degree of comorbidities such as obesity, coronary artery 
disease and diabetes mellitus. These conditions are per se linked to structural 
cardiac changes and an impairment in CFR, and thus may determine CFR inde-
pendently of the observed moderate changes in BP. (ii) No diagnostic method is 
available to measure the achieved degree of sympathetic denervation after inter-
vention. Given the relatively modest reduction in office BP and absence of sign-
ficant changes in ambulatory BP, an insufficient degree of RDN cannot be 
excluded entirely.  
 
Our findings stress the complex and multifactorial regulation of human coronary 
flow reserve. Study II raises questions about the impact of RDN on coronary 
microcirculation in the context of RH.   
 
 
The Swedish Registry for Renal Denervation: Renal denerva-
tion is safe and associated with sustained blood pressure re-
ductions  
 
The effects of RDN on BP in patients with RH have generated conflicting results 
(35, 51-54). Registry-data are a valuable complement to clinical trial data by 
testing the external validity of data acquired in selected trial populations (56).  
While studies I and II were mainly dedicated to pathophysiological aspects, 
Study III assesses the BP effects of RDN in a clinical setting.  
The observed BP reductions were in line with previous observational registry 
studies showing clinically potentially significant changes for both office and 
ambulatory BP and a good short- and long-term safety-profile (57-60). 
Study III is the first published report of a comprehensive nation-wide experience 
with RDN, i.e. RDN has not been performed outside this network of seven Swe-
dish university hospitals. Furthermore, our study contributes to the existing body 
of evidence by extending previously published observation periods and thereby 
providing further evidence on the long-term development of BP after RDN. Fi-
nally, we were able to provide a head-to-head comparison of the most commonly 
used ablation systems, which did not yield significant differences in regard to 
neither safety nor efficacy.  
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Does renal sympathetic denervation modulate afferent renal 
sympathetic nerve activity? 
 
Inhibition of afferent sympathetic nerve signals and a consecutive resetting of 
central sympathetic nerve activity constitute the major rationale for the devel-
opment of RDN (44).  
 
These potential changes, as assessed by MSNA, have been the subject of several 
studies in varying settings that have generated conflicting results. While some 
groups have shown a significant impact of RDN on MSNA (46, 48, 50), others 
have not been able to reproduce these positive results (45, 47, 49). Furthermore, 
only a few studies have been able to show a correlation between changes in 
MSNA and BP (50), which is considered to be an important link in the attempt 
to confirm this major hypothesis. 
 
Our findings from Study IV contribute to current knowledge in several different 
ways: (i) In confirmation of previous studies, we did not note significant changes 
in MSNA at rest after RDN, nor did we detect any correlation between changes 
in MSNA and BP. (ii) The assessment of MSNA during mental stress in patients 
with RH is a scientific novelty, and showed no detectable change in the pattern 
of either MSNA or cardiovascular reactivity during mental stress provocation. 
(iii). Finally, MSNA inhibition in patients with RH appears to be rare phenome-
non. This observation evokes associations with findings from previous studies, 
which have demonstrated that the lack of MSNA inhibition during mental stress 
predicts future development of hypertension in healthy subjects (84). As this 
matter may touch vital aspects of the pathophysiology of essential hypertension, 
we have initiated a larger study to provide further evidence on the occurrence of 
MSNA inhibition in patients with RH.  
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CONCLUSIONS  
Study 1 
RH was associated with an impairment in CFR as compared to controlled hyper-
tensives, which may contribute to the increased risk of cardiovascular morbidity 
and mortality in this patient population. CFR values differed despite a similar 
distribution in left ventricular mass, which indicates an advance degree of mi-
crovascular dysfunction in patients with RH. Further research is warranted to 
differentiate and quantify the importance of the different aspects of regulation of 
the coronary vessel tone in patients with advanced degrees of hypertension. 
Study II 
Regulation of CFR is a multifactorial process. Renal sympathetic denervation 
and its subsequent moderate changes in BP were not associated with modifica-
tions of CFR six months after the procedure.  
Study II 
RDN was associated with clinically relevant BP reductions in this observational, 
uncontrolled patient cohort. Our study emphasises the good safety and therapeu-
tic potential of RDN in the treatment of hypertension. Rigorously designed, ran-
domised trials are needed to confirm and contextualise the observed treatment 
effect.  
Study II 
We conclude that the changes in BP, as noted in our study, did not seem to de-
pend on changes in MSNA, either at rest or during mental stress. MSNA inhibi-
tion in patients with RH is a rare phenomenon, raising questions about the 
significance of MSNA inhibition in the pathophysiology of essential hyperten-
sion.  
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FUTURE PERSPECTIVE 
As illustrated by the results of this thesis, there are many open questions in the 
field of percutaneous renal sympathetic denervation. However, besides our own 
findings, substantial developments have been made during the course of this 
thesis:  
 
(i) Important study-design inherent confounders have been identified.  
 
(ii) New anatomical insights have changed established strategies during renal 
nerve ablation and have shifted the focus to a more aggressive and distal ap-
proach. 
 
(iii) New catheters have been developed in order to achieve a more reliable, cir-
cumferent vessel contact.  
 
(iv) Insights from previous studies have led to the identification of patient popu-
lations prone to respond to renal denervation.  
 
(v) Due to the abundance of confounding factors in patients with resistant hyper-
tension, the focus has shifted towards new patient populations, including those 
with less advanced stages of hypertension. 
 
Recently published and ongoing clinical trials have taken these novel insights 
into consideration and have generated promising data.  
 
As hypertension remains a major global health issue, renal denervation deserves 
the field’s continued scientific effort in order to identify its true potential.  
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